Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Angina Pectoris/MI
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Angina Pectoris/MI
    Certain Biomarkers Have Limitations in Predicting Cardiovascular Events - (DGNews)
    Routine early angioplasty after fibrinolysis for acute myocardial infarction - (N Engl J Med)
    Some Stroke Survivors' Function Slowly Declines Over Time - (DGNews)
    Migraine With Aura Frequency Plays a Role in Risk of Stroke, MI - (DGNews)
    TopAbstracts in Angina Pectoris/MI 06/24/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Angina Pectoris/MI
      Keys to Successful Outcomes from Anticoagulant and Antiplatelet Therapy: Addressing Medication Therapy Management Issues
      Cardiovascular Series: Guidelines for Anticoagulant and Antiplatelet Therapy in the Prevention and Treatment of Acute Coronary Syndrome: Incorporation into Clinical Practice
      Translating Evidence-Based Guidelines into Clinical Practice in the Management of Acute Coronary Syndrome
      Advancing the Standard of Care: Cardiovascular and Neurovascular Emergencies
      Anti-inflammatory and Anti-atherogenic Effects of Insulin

      Webcasts/CME archive

       Recent cases - Angina Pectoris/MI
        Giant Right Coronary Artery Aneurysm: Case Report and Literature Review
        Acute Myocardial Infarction and Pulmonary Embolism in a Young Man with Pernicious Anemia-Induced Severe Hyperhomocysteinemia
        Ultrasound In Evaluation of Post-Interventional Femoral Vein Obstruction: A Case Report
        Menstruation Angina: A Case Report
        Spontaneous Left Main Coronary Artery Dissection Complicated by Pseudoaneurysm Formation in Pregnancy: Role of CT Coronary Angiography

        Cases archive
          




        my personal edition > angina pectoris/mi > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Atorvastatin as Effective as Amlodipine for Reducing Ischaemia in Patients With Chronic Stable Angina: Presented at ACC

          By Bruce Sylvester

          CHICAGO -- April 2, 2008 -- Atorvastatin monotherapy is as effective as amlodipine monotherapy and a combination of the two drugs for reducing transient myocardial ischaemia (TMI) in patients with chronic stable angina, researchers reported here at the 57th Annual Scientific Session of the American College of Cardiology (ACC 2008).

          "What we found, very unexpectedly, was that the statin was as effective an antianginal and anti-ischaemic drug as the traditional medications we use for treating angina and ischaemia.," said lead investigator John Deanfield, MD, Professor of Cardiology, University College, London, United Kingdom. "Within 18 weeks, the statin had virtually eliminated any evidence of ischaemia during the patient's normal daily activity."

          In the Double-Blind Atorvastatin Amlodipine (DUAAL) study, Dr. Deanfield and colleagues randomised subjects with coronary artery disease and chronic stable angina to atorvastatin (n=103), amlodipine (n=104), or a combination of the two drugs (n=104). Subjects also received usual care therapy for coronary artery disease, which included beta-blockers, long acting nitrates, and aspirin.

          The randomised, double-blind, parallel-group, multi-country trial had a 2-week run-in phase followed by 24 weeks of active therapy, titrated at week 6.

          At endpoint, the investigators reported that TMI episodes decreased by 66%, and 50% of all subjects became TMI free in all 3 groups. The investigators also reported a marked reduction in angina and nitroglycerin consumption.

          Notably, atorvastatin therapy was as effective as amlodipine for relief of TMI.

          In addition, the inflammation marker C-reactive protein decreased by 40% among atorvastatin subjects, with no change among amlodipine subjects.

          Adverse events were comparable across groups.

          "This is a novel finding, and one which will interest most physicians," said Dr. Deanfield.

          Funding for this study was provided by Pfizer, Inc.


          [Presentation title: Effect of Amlodipine, Atorvastatin and the Combination on Transient Myocardial Ischemia in Coronary Artery Disease From the DUAAL Study. Poster 1032-42]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send